By VC News Daily
BERKELEY, CA, Radar Therapeutics, a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio.
Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined the round, with participation from PearVC, BEVC and other investors. The financing will support advancement of Radar’s internal programs, team expansion and partnering.
Radar Therapeutics is a biotech company developing programmable precision therapeutics. Leveraging innovative mRNA technology and proprietary regulatory control elements, the company aims to revolutionize medicine by enabling targeted, timely, and controlled therapeutic interventions. Radar is committed to advancing the boundaries of genetic medicine to address unmet medical needs and improve patient access.
(c) by Massinvestor, Inc. For contact info, please check out our about page.